Please login to the form below

Not currently logged in
Email:
Password:

CRISPR Therapeutics appoints Dr Tony Coles

He takes up a seat on the Swiss biopharma's board of directors

CRISPR Tony ColesSwiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors.

He is currently founding investor, chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company focused neurodegenerative diseases.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track record of success.

“The appointment of Dr Coles is in line with our effort to bring the best talent to CRISPR Therapeutics and rapidly become a leading biopharmaceutical company devoted to discovering and developing novel medicines for patients suffering from diseases with limited treatment options.”

Prior to founding Yumanity Dr Coles served as chairman and chief executive officer of Onyx Pharmaceuticals, which was acquired by Amgen in 2013 for $10.5bn.

He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck & Co.

6th January 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics